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Abstract
Background: To assess the efficacy of the intravitreal (IVT) injection of Triamcinolone Acetonide (TA) as
compared to posterior subtenon (SBT) capsule injection for the treatment of cystoid diabetic macular edema.
Methods: Fourteen patients with type II diabetes mellitus and on insulin treatment, presenting diffuse cystoid
macular edema were recruited. Before TA injection all focal lakes were treated by laser photocoagulation. In the
same patients one eye was assigned to 4 mg IVT injection of TA and the fellow eye was then treated with 40 mg
SBT injection of TA. Before and one, three and six months after treatment we measured visual acuity with ETDRS
chart as well as thickness of the macula with optical coherence tomography (OCT) and intraocular pressure
(IOP).
Results: The eyes treated with an IVT injection displayed significant improvement in visual acuity, both after one
(0.491 ± 0.070; p < 0.001) and three months (0.500 ± 0.089; p < 0.001) of treatment. Significant improvement
was displayed also in eyes treated with an SBT injection, again after one (0.455 ± 0.069; p < 0.001) and three
months (0.427 ± 0.065; p < 0.001). The difference between an IVT injection (0.809 ± 0.083) and SBT injection
(0.460 ± 0.072) becomes significant six months after the treatment (p < 0.001).
Macular thickness of the eyes treated with IVT injection was significantly reduced both after one (222.7 ± 13.4
µm; p < 0.001) and after three months (228.1 ± 10.6 µm; p < 0.001) of treatment. The eyes treated with SBT
injection displayed significant improvement after one (220.1 ± 15.1 µm; p < 0.001) and after three months (231.3
± 10.9 µm; p < 0.001). The difference between the eyes treated with IVT injection (385.2 ± 11.3 µm) and those
treated with SBT injection (235.4 ± 8.7 µm) becomes significant six months after the treatment (p < 0.001).
Intraocular pressure of the eyes treated with IVT injection significantly increased after one month (17.7 ± 1.1 mm/
Hg; p < 0.020), three (18.2 ± 1.2 mm/Hg; p < 0.003) and six month (18.1 ± 1.3 mm/Hg; p < 0.007) when compared
to baseline value (16.1 ± 1.402 mm/Hg). In the SBT injection eyes we didn't display a significant increase of
intraocular pressure after one (16.4 ± 1.2 mm/Hg; p < 0.450), three (16.3 ± 1.1 mm/Hg; p < 0.630) and six months
(16.2 ± 1.1 mm/Hg; p < 0.720) when compared to baseline value (16.2 ± 1.3 mm/Hg).
Conclusion: The parabulbar subtenon approach can be considered a valid alternative to the intravitreal injection.
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Background
Diabetic macular edema is one of the leading causes of
diabetes induced visual impairment and affects one third
of diabetic patients with disease duration of twenty years
or more [1]. Many studies, including the Early Treatment
Diabetic Retinopathy Study (ETDRS) have demonstrated
that macular photocoagulation is effective for the treat-
ment of macular edema [2,3] but does not usually restore
vision loss occurring before treatment [2,4]. Laser photo-
coagulation, however, only has a moderate effect in pre-
venting further visual loss in about 50% of patients [2,4].
Recently, there have been many reports of the effective-
ness of intravitreal triamcinolone acetonide (TA) for the
treatment of diffuse macular edema, refractory to laser
treatment [5,6].
Intravitreal triamcinolone injections are however associ-
ated with many ocular complications (i.e. ocular hyper-
tone, endophthalmitis, intraocular hemorrhages,
detachment of the retina) [5,7,6,8,9]. Parabulbar sub-
tenon injection of steroids appears to offer a good alterna-
tive for the treatment of diabetic macular edema and
intermediate uveitis [10,11]. This approach is less invasive
than intravitreal injection and may deliver equivalent
therapeutic quantities of TA to the retina [12].
The purpose of this study was to assess the efficacy of the
intravitreal (IVT) injection of TA as compared to posterior
subtenon (SBT) capsule injection for the treatment of cyst-
oid diabetic macular edema.
Methods
A total of 14 patients (28 eyes) were treated, 10 males and
4 females, aged between 61 and 74 years (mean 68.3),
with type II diabetes mellitus and on insulin treatment.
All patients were phakic and showed a diffuse macular
edema without retinal-vitreous traction. The patients were
recruited among patients treated by the Ophthalmology
Service of the S. Orsola-Malpighi Hospital, Bologna.
Before enrolment, patients were informed of the proce-
dures and the aim of the study and they signed a written
consent form. The institutional ethics committee of the S.
Orsola-Malpighi Hospital also approved the study. In all
the patients the best corrected logarithm of the minimum
angle of resolution (logMAR) visual acuity was assessed
using the Early Treatment Diabetic Retinopathy Study
(ETDRS) chart, as well as intraocular pressure (IOP)
applanation tonometry and anterior and posterior seg-
ment biomicroscopy. Macular edema was defined by cen-
tral thickening revealed with biomicroscopy using a 78-
diopter non-contact lens and by diffuse fluorescein leak-
age on fluorescein angiography (FA). Macular thickness
was measured by optical coherence tomography (OCT).
All focal lakes previously were treated by laser photocoag-
ulation.
Exclusion criteria included history of uveitis episodes, pre-
vious ocular surgery, glaucoma and ocular hypertension.
In the same patients one eye was assigned with a, random
method generated by a computer to intravitreal (IVT)
injection of TA. One week after the IVT treatment of the
first eye, and after excluding the appearance of complica-
tions (i.e. hypertone, vitreous hemorrhage, endoph-
thalmitis), the fellow eye was then treated with subtenon
(SBT) injection of TA. Two days before the IVT injection of
TA, to avoid post-operative hypertone, the patients were
prescribed a systemic treatment with acetazolamide, 250
mg two times daily.
For the IVT injection, the patient was placed supine and
we performed a surface anesthesia with topical 4% carbo-
caine followed by a preparation with 5% povidone
iodine. A volume of 0.1 ml containing 4 mg preservative-
free TA (Kenacort, Bristol-Myers Squibb, Sermoneta, Italy)
was injected through the inferotemporal pars-plana (4.0
mm posterior to the limbus) using a 30-gauge needle.
Indirect ophthalmoscopy was used to confirm correct
intravitreal localization of the suspension. After the injec-
tion topical 0.3% Netilmicin ointment was prescribed.
For the posterior SBT injection, the patient was placed
supine and after topical 0.4% oxybuprocaine surface
anesthesia a 1 ml of a 40 mg/ml of triamcinolone aceto-
nide (Kenacort, Bristol-Myers Squibb, Sermoneta, Italy)
was given in the inferotemporal quadrant using a 27-
gauge needle on 2.5-ml syringe. The patients were direct
to look in the extreme superonasal field of gaze. The con-
junctiva and the Tenon's capsule were penetrated with the
bevel of the needle toward the globe. The needle was
advanced toward the macular area, taking care to remain
in contact with the globe until the hub was firmly pressed
against the conjunctival fornix and then the corticosteroid
was slowly injected. After injection topical 0.3% Netilm-
icin ointment was prescribed.
For each patient in the group of SBT a B-scan examination
was performed before and immediately after the injection
to show the lucency in subtenon space representing the
repository triamcinolone acetonide just in the macular
area (Fig 1).
Subsequently, one, three and six months after treatment
visual acuity and IOP were measured in the patients as
well as thickness of the retinal macula with OCT.
The data were statistically evaluated using the Wilcoxon
signed rank test and a p < 0.05 was considered significant.BMC Ophthalmology 2008, 8:5 http://www.biomedcentral.com/1471-2415/8/5
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Data are presented as means ± standard deviation (SD).
The analysis was performed using SSI (version 11, Systat
Software Inc., San Jose, California, USA) for Macintosh.
Results
The mean visual acuity before triamcinolone acetonide
injection and after one, three and six months after are
showed in Table 1. The eyes treated with an IVT injection
displayed significant improvement in visual acuity, both
after one month (0.491 ± 0.070; p < 0.001) and after three
months (0.500 ± 0.089; p < 0.001) of treatment when
compared to the baseline values (0.836 ± 0.112). Signifi-
cant improvement was displayed also in eyes treated with
an SBT injection, again after one month (0.455 ± 0.069; p
< 0.001) and after three months (0.427 ± 0.065; p <
0.001) when compared to the baseline values (0.864 ±
0.103). The difference of visual acuity between eyes
treated with an IVT injection and those treated with an
SBT injection becomes significant six months after the
treatment (p < 0.001). The eyes treated with IVT in fact
display significant worsening of visual acuity (0.809 ±
0.083) whereas eyes treated with SBT maintain visual acu-
ity improvement (0.460 ± 0.072).
The macular thickness before triamcinolone acetonide
injection and after one, three and six months are showed
in Table 2. The macular thickening of the eyes treated with
IVT injection is concerned, thickness was significantly
reduced both after one month (222.7 ± 13.4 µm; p <
0.001) and after three months (228.1 ± 10.6 µm; p < 0.01)
when compared to the baseline values 386.3 ± 12.4 µm.
The eyes treated with SBT injections displayed significant
improvement after one month (220.1 ± 15.1 µm; p <
0.001) and after three months (231.3 ± 10.9 µm; p <
0.001) of treatment when compared to the baseline values
of 384.1 ± 18.9 µm. Here too the difference in retinal mac-
ular thickness of the eyes treated with IVT (385.2 ± 11.3
µm) and those treated with SBT (235.4 ± 8.7 µm)
becomes significant six months after the treatment (p <
0.001). Fig 2 illustrates the changes in the OCT images of
a representative patient in the SBT injection group.
The mean intraocular pressure before triamcinolone ace-
tonide injection and after one, three and six months are
showed in Table 3. The IOP of the eyes treated with IVT
injection was significantly increased after one month
(17.7 ± 1.1 mm/Hg; p < 0.020), three months (18.2 ± 1.2
mm/Hg; p < 0.003) and six months (18.1 ± 1.320 mm/
Hg; p < 0.007) when compared to baseline value (16.1 ±
1.4 mm/Hg) but none glaucoma medication was needed
to control the IOP. The eyes treated with SBT injection dis-
played not significant increase of the IOP not only after
one month (16.4 ± 1.2 mm/Hg; p < 0.450) but also after
three (16.3 ± 1.1 mm/Hg; p < 0.630) and six months
(16.2 ± 1.1 mm/Hg; p < 0.720) when compared to base-
line value (16.2 ± 1.3 mm/Hg). The difference of IOP
between eyes treated with an IVT injection and those
Table 1: Visual acuity before and after IVT and SBT 
triamcinolone injection. Visual acuity with log/MAR resolution in 
the intravitreal and posterior subtenon injected eyes at baseline 
and at 1, 3 and 6 months after triamcinolone acetonide 
injection.
IVT Visual Acuity SBT Visual Acuity p < 0.05
Baseline 0.836 ± 0.112 0.864 ± 0.103 0.625
1 month 0.491 ± 0.070 0.455 ± 0.069 0.161
3 months 0.500 ± 0.089 0.427 ± 0.065 0.070
6 months 0.809 ± 0.083 0.460 ± 0.072 0.001
Echographic images before and after subtenon triamcinolone  injection Figure 1
Echographic images before and after subtenon tri-
amcinolone injection. Echographic B-scan image before 
(A) and after (B) posterior subtenon triamcinolone acetonide 
injection where the lucency (white arrow) representing 
repository corticosteroid.BMC Ophthalmology 2008, 8:5 http://www.biomedcentral.com/1471-2415/8/5
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OCT images before and after subtenon triamcinolone injection Figure 2
OCT images before and after subtenon triamcinolone injection. Optical coherence tomography map of diabetic cyst-
oid macular edema before (A) and six months after (B) posterior subtenon triamcinolone acetonide injection.BMC Ophthalmology 2008, 8:5 http://www.biomedcentral.com/1471-2415/8/5
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treated with an SBT injection becomes significant at three
(p < 0.026) and six (p < 0.030) months.
Discussion
This study demonstrates that three months after the intra-
vitreal injection of TA and the subtenon injection of TA
there is a statistically significant improvement in visual
acuity and an equally significant reduction in retinal
thickness. Six months after IVT the patients presented a
recurrence of macular edema with loss of visual acuity
whereas six months after SBT injection retinal thickness
and visual acuity remained stable. After one, three and six
months we observed a statistically significant rise of the
IOP in the eyes treated with IVT injection whereas in the
SBT injection group, no statistically significant variations
of the IOP were found. None of patients developed cata-
ract or needed anti-glaucoma drugs during the follow-up.
Macular edema is the main cause of loss of visual acuity in
diabetic patients [13,14]. It may occur at any stage of the
retinal disorder and is the most common cause of sight
reductions in these subjects.
In the edema, the hemato-retinal barrier is damaged by an
alteration in the tight junction between the retinal capil-
lary endothelial cells and the pigmented epithelial cells
with the consequent leakage of water and electrolytes in
the retinal tissue [3,15-17].
As has been seen in numerous studies, including the Early
Treatment Diabetic Retinopathy Study (ETDRS), macular
photocoagulative treatment is effective in the treatment of
clinically important macular edema [2,18,3].
Thus laser photocoagulation for macular edema, although
successful in blocking further visual loss in 50% of
patients, is unable to restore visual loss occurring prior to
treatment [2,4]. Moreover, laser photocoagulation is not
very effective in eyes with diffuse macular edema [19,20].
The extent of the restoration of the hemato-retinal barrier
functioning following laser treatment is debated as many
studies indicate an increase in the edema following laser
photocoagulation [20-22] probably as a result of the
release of proinflammatory molecules. Indeed, the initial
clinical pattern of diabetic retinopathy, with vasodilata-
tion, increased blood flow, tissue edema and an increase
in the vascular permeability presents the characteristics of
chronic inflammation. This hypothesis is supported by
recent studies, which have highlighted the appearance of
leukostasis in diabetes [23] with adhesion of activated
molecules to the endothelium [24], increased production
of prostacyclin [25], vascular endothelial growth factor
(VEGF) and macrophagic cellular component [26].
Further support for the thesis of inflammation as one of
the causes of onset of diabetic retinopathy is provided by
experimental studies in animals which demonstrate how
hyperglycemias not only causes an increase in the produc-
tion of cycloxygenase-2 (COX2), through the activation of
protein-kinase (PKC) [27,28], but also in prostaglandin
synthetase (PGIS) [29] a specific enzyme in the synthesis
of prostaglandin PGI2 [30]. Furthermore, recent studies
have confirmed the important role of COX2 and the pros-
tanoids in the onset of renal damage in patients with
impaired glycemic control.
The fall in the prostacyclin levels only occurs in the
advanced stage of diabetic microangiopathy. This is con-
firmed not only by the reduction in the blood PGI2 levels
but also by the reduction in the PGE values observed at a
vitreous level during proliferative diabetic retinopathy
[31].
All these experimental and clinical data confirm the
involvement of pro-inflammatory molecules that also
cause a subclinical increase in the aqueous humor cells in
the early stages of diabetic retinopathy [32].
Table 2: Macular thickness before and after IVT and SBT triamcinolone injection. Central macular thickness (µm) in the intravitreal 
and posterior subtenon injected eyes at baseline and at 1, 3 and 6 months after triamcinolone acetonide injection.
IVT Macular Thickness SBT Macular Thickness p < 0.05
Baseline 386.3 ± 12.4 384.1 ± 18.9 0.721
1 month 222.7 ± 13.4 220.1 ± 15.1 0.625
3 months 228.1 ± 10.6 231.3 ± 10.9 0.580
6 months 385.2 ± 11.3 235.4 ± 8.7 0.001
Table 3: Intraocular pressure before and after IVT and SBT 
triamcinolone injection. Intraocular pressure (mm/Hg) in the 
intravitreal posterior subtenon and injected eyes at baseline and 
at 1, 3 and 6 months after triamcinolone acetonide injection.
IVT-IOP SBT-IOP p < 0.05
Baseline 16.1 ± 1.4 16.2 ± 1.3 0.140
1 month 17.7 ± 1.1 16.4 ± 1.2 0.062
3 months 18.2 ± 1.2 16.3 ± 1.1 0.026
6 months 18.1 ± 1.3 16.2 ± 1.1 0.030BMC Ophthalmology 2008, 8:5 http://www.biomedcentral.com/1471-2415/8/5
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Recent studies have shown that intravitreal injections of
TA have a positive effect on those forms of diabetic macu-
lar edema that are refractory to retinal laser treatment
[5,7,6]. The use of corticosteroids for the treatment of ret-
inal edema is linked to their capacity to inhibit the initial
arachidonic acid cascade, to determine a down-regulation
of the cytokines and to attenuate the tearing of the
hemato-retinal barrier [7,15,33].
The use of intravitreal TA is not however without risks
[6,12]. The main complications are endophthalmitis,
intraocular hemorrhages, detachment of the retina
[5,7,6,8,9] and possible increases in IOP in a percentage
of cases varying from 20% to 80% [7,6,34,35]. Finally, the
intravitreal administration of corticosteroids is only effec-
tive for a few months [36], which means that it is neces-
sary to repeat the injections at three-monthly intervals to
maintain stability of the retinal macula.
The subtenon TA administration has already been used in
the treatment of cystoid macular edema and intermediate
uveitis [10,11]. This administration route is not consid-
ered ideal to obtain a therapeutic dose of cortisone at the
level of the retina [37] although this opinion can be con-
tested on the basis of the clinical results and the ultra-
sound investigations which demonstrate how a correct
administration of the injection makes it possible to
deposit the drug in the macular area [38-40].
The subtenon approach is clearly less invasive than the
intravitreal one [39] although, here again, this commonly
used method is not free of potential complications such as
the accidental injection directly into the choroidal or reti-
nal circulation, perforation of the ocular bulb, occlusion
of the central retinal artery and cataract [39]. Other com-
plications described are blepharoptosis, orbital fat atro-
phy, strabismus and conjunctival necrosis [39,41]. IOP is
not increased by the use of this approach with the excep-
tion of steroid responder patients [39,41].
This study has attempted to simplify the subtenon injec-
tion technique even further by using a 27 gauge needle,
generally used for parabulbar anesthetics in cataract sur-
gery. This approach made it possible to administer the
injection without having to create a surgical opening in
the conjunctiva to access the subtenon space, thus
improving patient compliance with this therapy. When
we use the subtenon approach for TA injection it is very
important to make a careful echographic examination to
determine the correct location near the macula of the
drug. Without echography we cannot determine whether
an unsatisfactory therapeutic response is secondary to the
disease process or to misdisplacement of the TA. We think
that our good results with the SBT approach in this study
is related to the correct placement of TA near the macular
area displayed with the echographic images.
Conclusion
This study, although involving a limited number of
selected patients, indicates how the eyes given a subtenon
injection benefited from a more prolonged therapeutic
efficacy of triamcinolone.
The subtenon approach, when the triamcinolone aceto-
nide is correctly placed in the subtenon spaces, can be
considered an easy, safe and valid alternative to the intra-
vitreal injection.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MC recruited the patient from the Retina Disease Service
of the S. Orsola-Malpighi Hospital, he drafted the manu-
script and performed the subtenon TA injection. AP per-
formed the intravitreal TA injection. EZ reviewed the
literature, PL examined the patient in the time and ECC
review the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
This work was supported in part through University of Bologna (ECC-
MIUR ex-60%), in part from a grant of the "Fondazione Banca del Monte di 
Bologna e Ravenna" and in part through a gift of the "Fondazione Cassa di 
Risparmio di Bologna".
The authors thank Mrs. Juliet Macan for English review of the manuscript.
References
1. Klein R, Klein BE, Moss SE: The Wisconsin epidemiologic study
of diabetic retinopathy. IV. Diabetic macular edema.  Ophthal-
mology 1984, 91:1464-1474.
2. Early Treatment Diabetic Retinopathy Study Research
Group. Photocoagulation for diabetic macular edema. Early
Treatment Diabetic Retinopathy Study report number 1.
Arch Ophthalmol 1985, 103:1796-1806.
3. Aiello LM: Perspectives on diabetic retinopathy.  Am J Ophthal-
mol 2003, 136:122-135.
4. Akduman L, Olk RJ: Laser photocoagulation of diabetic macu-
lar edema.  Ophthalmic Surg Lasers 1997, 28:387-408.
5. Massin P, Audren F, Haouchine B: Intravitreal triamcinolone ace-
tonide for diabetic diffuse macular edema: preliminary
results of a prospective controlled trial.  Ophthalmology 2004,
111:218-24.
6. Jonas JB, Kreissig I, Sofker A, Degenring RF: Intravitreal injection
of triamcinolone for diffuse diabetic macular edema.  Arch
Ophthalmol 2003, 121:57-61.
7. Martidis A, Duker JS, Greenberg PB: Intravitreal triamcinolone
for refractory diabetic macular edema.  Ophthalmology 2002,
109:920-927.
8. Moshfeghi DM, Kaiser PK, Scott IU: Acute endophthalmitis fol-
lowing intravitreal triamcinolone acetonide injection.  Am J
Ophthalmol 2003, 136:791-796.
9. Jonas JB, Kreissig I, Degenring R: Secondary chronic open-angle
glaucoma after intravitreal triamcinolone acetonide.  Arch
Ophthalmol 2003, 121:729-730.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Ophthalmology 2008, 8:5 http://www.biomedcentral.com/1471-2415/8/5
Page 7 of 7
(page number not for citation purposes)
10. Helm CJ, Holland GN: The effects of posterior subtenon injec-
tion of triamcinolone actetonide in patients with intermedi-
ate uveitis.  Am J Ophthalmol 1995, 120:55-64.
11. Thach AB, Dugel PU, Flindall RJ: A comparison of retrobulbar
versus sub-Tenon's corticosteroid therapy for cystoid macu-
lar edema refractory to topical medications.  Ophthalmology
1997, 104:2003-2008.
12. Geroski DH, Edelhauser HF: Transcleral drug delivery for poste-
rior segment disease.  Adv Drug Deliv Rev 2001, 52:37-48.
13. Moss SE, Klein R, Klein BE: Ten-year incidence of visual loss in a
diabetic population.  Ophthalmology 1994, 101(6):1061-1070.
14. Moss SE, Klein R, Klein BE: The 14-year incidence of visual loss
in a diabetic population.  Ophthalmology 1998, 105(6):998-1003.
15. Aiello LP: The potential role of PTK beta in diabetic retinop-
athy and macular edema.  Surv Ophthalmol 2002,
47(suppl):S263-9.
16. Sander B, Larsen M, Moldow B, Lund-Andersen H: Diabetic macu-
lar edema: passive and active transport of fluorescein
through the blood-retina barrier.  Invest Ophthalmol Vis Sci 2001,
42:433-438.
17. Kent D, Vinores SA, Campochiaro PA: Macular edema: the role
of soluble mediators.  Br J Ophthalmol 2000, 84:542-545.
18. Early Treatment Diabetic Retinopathy Study Research
Group. Treatment techniques and clinical guidelines for
photocoagulation of diabetic macular edema. Early Treat-
ment Diabetic Retinopathy Study report number 2.  Ophthal-
mology 1987, 94:761-774.
19. Lee CM, Olk RJ: Modified grid laser photocoagulation for dif-
fuse macular edema: long-term visual results.  Ophthalmology
1991, 98:1594-1602.
20. Early Treatment Diabetic Retinopathy Study Research
Group. Focal photocoagulation treatment of diabetic macu-
lar edema. Relationship of treatment effect to fluorescein
angiographic and other retinal characteristics at baseline:
ETDRS report no.19.  Arch Ophthalmol 1995, 113:1144-1155.
21. Nanoka A, Kiryu J, Tsujikawa A: Inflammatory response after
scatter laser photocoagulation in nonphotocoagulated ret-
ina.  Invest Ophthalmol Vis Sci 2002, 43:1204-1209.
22. Hudson C, Flanagan JG, Turner GS: Correlation of a scanninig
laser derived edema index and visual function following grid
laser treatment for diabetic macular edema.  Br J Ophthalmol
2003, 87:455-461.
23. Barouch FC, Miyamoto K, Allport JR: Integrin-mediated neu-
trophil adhesion and retinal leukostasis in diabetes.  Invest
Ophthamol Vis Sci 2000, 41(5):1153-1158.
24. Miyamoto E, Khosrof S, Bursell SE: Prevention of leukostasis and
vascular leakage in streptozotocin-induced diabetic retinop-
athy via intercellular adhesion molecule-1 inhibition.  Proc
Natl Acad Sci USA 1999, 96:10836-10841.
25. Hata Y, Clermont A, Yamauchi T: Retinal expression. regulation.
and functional bioactivity of prostacyclin-stimulating factor.
J Clin Invest 2000, 106:541-550.
26. Takagi H, Otani A, Kiryu J, Ogura Y: New surgical approach for
removing foveal hard exudates in diabetic macular edema.
Ophthalmology 1999, 106:249-256.
27. Tesfamariam B, Brown ML, Cohen RA: Elevated glucose impairs
endothelium-dependent relaxation by activating protein
kinase C.  J Clin Invest 1991, 87:1643-1648.
28. Mayhan WG, Patel KP: Acute effects of glucose on reactivity of
cerebral microcirculation: role of activation of protein
kinase C.  Am J Physiol 1995, 269(4):11297-11302.
29. Casentino F, De Paolis P, van der Loo B, Bachschmid M, Ullrich V,
Kouroedov A, Delli Gatti C, Joch H, Volpe M, Lüscher TF: High Glu-
cose Causes Upregulation of Cyclooxygenase-2 and alters
Prostanoid Profile in Human Endothelial Cells. Role of Pro-
tein Kinase C and Reactive Oxygen Species.  Circulation 2003,
107:1017-1023.
30. Hara S, Miyata A, Yokoyama C: Isolation and molecular cloning
of prostacyclin synthase from bovine endothelial cells.  J Biol
Chem 1994, 269:19897-19903.
31. Douros S, Phillips BA, Nadel A, Obstbaum SA: Human vitreal pros-
taglandin levels and proliferative diabetic retinopathy.  Doc
Ophthalmol 2001, 103(1):27-34.
32. Cellini M, Baldi A, Bernabini B, Leonetti P, Campos EC: Diabetic
retinopathy and laser flare cell-meter.  It Ophthalmol Bull 2005,
84:95-102.
33. Wilson CA, Berkowitz BA, Sato Y: Treatment with intravitreal
steroid reduces blood-retinal barrier breakdown due to ret-
inal photocoagulation.  Arch Ophthalmol 1992, 110:1155-1159.
34. Wingate RJ, Beaumont PE: Intravitreal triamcinolone and ele-
vated intraocular pressure.  Aust N Z J Ophthalmol 1999,
27:431-432.
35. Smithen LM, Ober MD, Maranan L, Spaide RF: Intravitreal triamci-
nolone acetonide and intraocular pressure.  Am J Ophthalmol
2004, 138:740-743.
36. Beer PM, Bakri JS, Singh RJ: Intraocular concentration and phar-
macokinetics of triamcinolone acetonide after a single intra-
vitreal injection.  Ophthalmology 2003, 110:681-686.
37. Inoue M, Takeda K, Morita K: Vitreous concentrations of triam-
cinolone acetonide in human eyes after intravitreal or sub-
tenon injection.  Am J Ophthalmol 2004, 138:1046-1048.
38. Freeman WR, Green RL, Smith RE: Echographic localization of
corticosteroids after periocular injection.  Am J Ophthalmol
1987, 103:281-288.
39. Mueller AJ, Jian G, Banker AS: The effect of deep posterior sub-
tenon injection of corticosteroids on intraocular pressure.
Am J Ophthalmol 1998, 125:158-163.
40. Thomas ER, Wang J, Ege E, Madsen R, Hainsworth DP: Intravitreal
Triamcinolone Acetonide concentration after subtenon
injection.  Am J Ophthalmol 2006, 142:860-861.
41. Agrawal S, Agrawal J, Agrawal TP: Conjunctival ulceration follow-
ing triamcinolone injection.  Am J Ophthalmol 2003, 136:539-540.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2415/8/5/prepub